Voya Investment Management LLC grew its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 21.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 875,577 shares of the biopharmaceutical company’s stock after acquiring an additional 156,345 shares during the quarter. Voya Investment Management LLC owned about 0.83% of Lexicon Pharmaceuticals worth $14,403,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Parametric Portfolio Associates LLC bought a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth about $182,000. First Mercantile Trust Co. increased its holdings in Lexicon Pharmaceuticals by 11.2% in the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 1,227 shares in the last quarter. Cim Investment Mangement Inc. bought a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth about $262,000. Pacad Investment Ltd. bought a new stake in Lexicon Pharmaceuticals in the 2nd quarter worth about $265,000. Finally, Legal & General Group Plc increased its holdings in Lexicon Pharmaceuticals by 2.6% in the 2nd quarter. Legal & General Group Plc now owns 18,570 shares of the biopharmaceutical company’s stock worth $305,000 after buying an additional 465 shares in the last quarter.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ LXRX) opened at 12.28 on Thursday. The company has a 50-day moving average price of $13.53 and a 200 day moving average price of $15.00. The company’s market capitalization is $1.30 billion. Lexicon Pharmaceuticals, Inc. has a 12-month low of $11.62 and a 12-month high of $19.50.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. The company had revenue of $12.00 million for the quarter, compared to analyst estimates of $18.34 million. During the same period in the prior year, the company posted ($0.37) EPS. The firm’s quarterly revenue was down 40.3% compared to the same quarter last year. On average, equities analysts anticipate that Lexicon Pharmaceuticals, Inc. will post ($1.46) earnings per share for the current fiscal year.

In other Lexicon Pharmaceuticals news, insider Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Friday, September 15th. The shares were bought at an average cost of $12.54 per share, with a total value of $376,200.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.77% of the company’s stock.

WARNING: This news story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/05/voya-investment-management-llc-has-14-40-million-stake-in-lexicon-pharmaceuticals-inc-lxrx.html.

LXRX has been the subject of several research analyst reports. BidaskClub downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. Needham & Company LLC reiterated a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. Finally, Cowen and Company reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $28.75.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Stock Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.